SIMPLYBOOK.ME
8.2.2021 19:31:11 CET | Business Wire | Press release
The SimplyBook.me appointment scheduling system, originally created as a solution for a popular tire workshop in Iceland, is now processing millions of Covid vaccination and Covid test bookings worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210208005729/en/
Early 2020, when the pandemic started to spread, the management and staff of SimplyBook.me worried how it might affect the company and its future with the core clients being smaller service businesses. The management team took the stand to use the company's reserve funds to keep all its qualified staff, even though the situation might drag on for months. At the same time, work began to evaluate if SimplyBook.me could find its place in the fight against the spread of the virus.
At this point, widespread Covid testing had not begun, and social distancing and masks were the order of the day. The team immediately identified opportunities to help with organising social distancing as well as Covid testing. Despite the bombardment of cancellation requests from smaller service businesses using the software that experienced lockdowns and inability to function, the COVID-related services continued to grow stronger.
NHS in the UK approached SimplyBook.me during the summer of 2020 as they needed a booking solution to help them organise Covid testing in one of their areas. We jumped on the opportunity and fine-tuned our software to customise to their needs. The results spoke for themselves, and more and more NHS trusts joined up to use the software. When it became apparent that the UK was going to be the first to start vaccinating, SimplyBook.me put the full force of their development and support teams on setting up the software so it would work for vaccinations in the best way possible.
"The project leader and team we've been working with at the NHS, are outstanding in their work and organisation. I sincerely hope the UK administration understands the quality of all the people working behind the scenes so that everything works as planned. They are incredibly professional and demand nothing less than perfection" said Ingvar Gudmundsson founder and VP-Sales at SimplyBook.me. "It is a privilege to work with such dedicated people who are doing their utmost to deliver the best."
"It is now early 2021, and we are proud to have taken a direct part in the fight against the virus throughout the past ten months. The cherry on the top is knowing that we are now being used for vaccination scheduling, processing millions of bookings in only the first few weeks since it started. We were always confident that we had built a great flexible software, adaptable to be used in all sorts of situations. This original vision has helped us grow faster than ever, keep all staff fully employed, and finally be at the forefront in the fight against the biggest plague of the last century."
________________________________________________________________________
SimplyBook.me is one of the world's top booking systems – a 360-degree software service which acts as a growth tool for SMEs, health organisations and educational institutions. The SimplyBook.me mission is bringing people and service businesses together by enabling them to easily book their services online no matter where, when or which.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005729/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Quantum Computer Goes Live at Supercomputing Center CINECA in Italy, Boosting National Compute Infrastructure and Research11.6.2026 14:50:00 CEST | Press release
The system will enable advanced applications in optimization, simulation, and machine learning. IQM Radiance quantum computer, featuring a 54-qubit processing unit. The system is being integrated into Leonardo, one of the world's fastest supercomputers. This is the second IQM quantum computer to be operational in Italy. The Italian Research Centre on High Performance Computing, Big Data, and Quantum Computing (ICSC) today inaugurated the IQM Radiance 54 quantum computer at CINECA, one of Europe's leading supercomputing centers, enabling advanced applications in optimization, simulation, and machine learning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611898215/en/ The moment Italy's second IQM quantum computer went live at CINECA in Bologna. IQM has previously announced its ongoing business combination with Real Asset Acquisition Corp (Nasdaq: RAAQ), which will result in IQM becoming a public company in mid-2026. The
Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release
Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release
Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom